CA Patent

CA2770077A1 — Formulations comprising linaclotide

Assigned to Forest Laboratories Holdings ULC · Expires 2011-02-10 · 15y expired

What this patent protects

The present invention relates to stable pharmaceutical dosage forms comprising linaclotide, as well as uses thereof, for treating gastrointestinal disorders including irritable bowel syndrome, for example constipation-predominant irritable bowel syndrome, and constipation, for ex…

USPTO Abstract

The present invention relates to stable pharmaceutical dosage forms comprising linaclotide, as well as uses thereof, for treating gastrointestinal disorders including irritable bowel syndrome, for example constipation-predominant irritable bowel syndrome, and constipation, for example chronic constipation. The stable dosage forms comprise a sterically hindered primary amine component and a metal cation component. In some embodiments, the sterically hindered primary amine component is leucine and the metal cation is Ca2+ or a salt thereof. The stable dosage forms may also comprise a polymer.

Drugs covered by this patent

Patent Metadata

Patent number
CA2770077A1
Jurisdiction
CA
Classification
—
Expires
2011-02-10
Drug substance claim
No
Drug product claim
No
Assignee
Forest Laboratories Holdings ULC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.